LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
26. Februar 2024 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
Agreement Focuses on Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and...
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
03. März 2023 08:00 ET
|
Daxor Corporation
Oak Ridge, TN, March 03, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today issued a corporate update in a Letter to...
Daxor Corporation Reports a 37% Increase in NAV to $6.75 Per Share for the Year Ended December 31, 2022
02. März 2023 07:00 ET
|
Daxor Corporation
Conference Call to be held today at 9:00 AM EST Oak Ridge, TN, March 02, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, filed...
Daxor Corporation to Report Fiscal Year 2022 Financial Results on Wednesday, March 1, 2023 and Provide Corporate Update
01. März 2023 08:00 ET
|
Daxor Corporation
Conference Call to be held at 9 AM EST March 2, 2023 Oak Ridge, TN, March 01, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology,...
Daxor Corporation Appoints Linda Cooper, Vice President Project Management
17. Februar 2023 08:00 ET
|
Daxor Corporation
Oak Ridge, TN, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the appointment of Linda Cooper as Vice...
Daxor Corporation Joins the Heart Failure Society of America (HFSA) as a Corporate Member
19. Januar 2023 08:00 ET
|
Daxor Corporation
Oak Ridge, TN, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces joining the Heart Failure Society of...
Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2023 Critical Care Congress
13. Januar 2023 08:00 ET
|
Daxor Corporation
Oak Ridge, TN, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be presenting at the Society for...
Newly Published Study Proves Value and Clinical Benefit of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure
03. Januar 2023 08:00 ET
|
Daxor Corporation
Study Shows Direct Volume Measurement’s Accuracy Compared to Pressure Measures Oak Ridge, TN, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume...
Daxor Corporation Announces Pricing of $2.0 million Underwritten Public Offering
15. November 2022 08:45 ET
|
Daxor Corporation
Oak Ridge, TN, Nov. 15, 2022 (GLOBE NEWSWIRE) -- DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the pricing of...
Daxor Corporation Announces Launch of Proposed Underwritten Public Offering
14. November 2022 17:03 ET
|
Daxor Corporation
Oak Ridge, TN, Nov. 14, 2022 (GLOBE NEWSWIRE) -- DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced that it has...